Last reviewed · How we verify

NCT05165147

Analysis the Positive Rate of Tumor Markers Among Physical Examination Population

Completed Last updated 21 December 2021
What this trial tests

trial testing no intervention in Tumor in 26,891 participants. Completed in 31 December 2019.

Timeline
1 January 2019
Primary endpoint
31 December 2019
31 December 2019

Quick facts

Lead sponsorPeking University Third Hospital
StatusCompleted
Study typeOBSERVATIONAL
Enrollment26,891
Start date1 January 2019
Primary completion31 December 2019
Estimated completion31 December 2019
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

Peking University Third Hospital

Who can join

Eligibility, any sex, with Tumor. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To analyze the positive rate of tumor markers (TM) among health examination population in a tertiary grade A class hospital, compare the differences between different age and sex groups, and explore the possible influencing factors of TM positive.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of no intervention

Trials testing the same drug.

Other recruiting trials for Tumor

Currently open trials in the same condition.

Other Peking University Third Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05165147.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing